R 803

Drug Profile

R 803

Alternative Names: R-803

Latest Information Update: 16 Jun 2005

Price : $50

At a glance

  • Originator Rigel Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 31 Dec 2004 Discontinued - Phase-I for Hepatitis C in United Kingdom (PO)
  • 31 Dec 2004 Discontinued - Phase-I/II for Hepatitis C in USA (PO)
  • 29 Nov 2004 Data from a media release have been added to the adverse events, pharmacokinetics and Viral Infections therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top